United States

» Auto updated continuously

• Source limited to: TheStreet

 2020-12-06 00:46 

The Street

Statement By The Prime Minister On The Death Of The Honourable Ronald A. Irwin...

OTTAWA, ON, Dec. 5, 2020 /CNW/ - The Prime Minister, Justin Trudeau, today issued the following statement on the death of the Honourable Ronald A. Irwin: "It was with sadness that I learned of the passing of former Sault Ste. Marie Mayor, Member of Pa...

 2020-12-05 23:32 

The Street

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses On Their Investment In Mesoblast Limited Of Class Action Law Suit And Upcoming Deadline - MESO...

NEW YORK, Dec. 5, 2020 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Mesoblast Limited ("Mesoblast" or the "Company") MESO and certain of its officers. The class action, filed in United States D...

 2020-12-05 23:00 

The Street

GlycoMimetics' Uproleselan In Combination With Venetoclax/HMA Shown To Break Chemoresistance, Reduce Tumor Burden And Increase Survival In AML Model...

GlycoMimetics' (Nasdaq: GLYC) product candidate uproleselan — when added to a combination therapy of venetoclax and a hypomethylating agent (HMA) — was shown today in an oral presentation to break chemoresistance by dramatically and signif...

 2020-12-05 22:00 

The Street

Janssen Presents First Data From The Phase 1 Study Of The GPRC5DxCD3 Bispecific Talquetamab In Patients With Relapsed Or Refractory Multiple Myeloma...

RARITAN, N.J., Dec. 5, 2020 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today initial data for the Phase 1 first-in-human dose escalation study of talquetamab (JNJ-64407564) for the treatment of relapsed or refracto...

 2020-12-05 20:17 

The Street

Updated Results From The Phase 1 Study Of The BCMAxCD3 Bispecific Teclistamab Show Preliminary Efficacy In Patients With Heavily Pretreated Relapsed Or Refractory Multiple Myeloma...

RARITAN, N.J., Dec. 5, 2020 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today updated results from an ongoing Phase 1 first-in-human dose escalation study ( NCT03145181) of teclistamab (JNJ-64007957) for the treatme...

 2020-12-05 20:01 

The Street

ImmunoGen Presents Updated Findings From Phase 1/2 Study Of IMGN632 In Blastic Plasmacytoid Dendritic Cell Neoplasm At ASH Annual Meeting...

ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that new safety and efficacy findings from the expansion phase of the Phase 1/2 study of IMGN632 in patients wit...

 2020-12-05 20:01 

The Street

Autolus Therapeutics Presents Compelling AUTO1 Data From ALLCAR Phase 1 Study In Adult Acute Lymphoblastic Leukemia (ALL) During The 62nd ASH Annual Meeting...

Updated data from the ALLCAR study suggests AUTO1's potential for transformational activity in adult patients with r/r ALL Conference call and webcast to be held Monday, December 7, 2020 at 4:00 pm ET / 9:00 pm GMT LONDON, Dec. 05, 2020 (GLOBE NEWSWIR...

 2020-12-05 20:00 

The Street

Legend Biotech Announces Phase 1b/2 Study Data Of Cilta-cel, An Investigational BCMA CAR-T, Showing Early, Deep, And Durable Responses In Heavily Pretreated Patients With Multiple Myeloma...

Legend Biotech Corporation LEGN ("Legend Biotech"), a global clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and other indications, today announced the latest data results from...

 2020-12-05 20:00 

The Street

Early, Deep, Durable Responses Of Ciltacabtagene Autoleucel (cilta-cel) Observed In Phase 1b/2 CARTITUDE-1 Study Show Potential Of BCMA CAR-T In Treatment Of Heavily Pretreated Patients With Multiple ...

RARITAN, N.J., Dec. 5, 2020 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today longer-term results from the combined Phase 1b/2 CARTITUDE-1 study ( NCT03548207) evaluating the efficacy and safety of ciltacabtagene au...

 2020-12-05 20:00 

The Street

Amgen To Present First Clinical Data For BCMA-Targeted Half-Life Extended BiTE Therapy AMG 701 At ASH 2020...

THOUSAND OAKS, Calif., Dec. 5, 2020 /PRNewswire/ -- Amgen AMGN today announced the first presentation of clinical safety and efficacy data from the Phase 1 study of AMG 701 in heavily pre-treated patients with relapsed/refractory multiple myeloma (R/R MM)...

 2020-12-05 19:45 

The Street

ROSEN, TRUSTED INVESTOR COUNSEL, Reminds Intercept Pharmaceuticals, Inc. Investors Of Important Deadline In Securities Class Action; Encourages Investors With Losses In Excess Of $100K To Contact The ...

Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Intercept Pharmaceuticals, Inc. ICPT between September 28, 2019 and October 7, 2020, inclusive (the "Class Period"), of the important January 4, 2021 lead p...

 2020-12-05 19:14 

The Street

Orange County Real Estate Agent Promotes Homes To MORE Buyers For MORE Money...

ANAHEIM, Calif. and FULLERTON, Calif., Dec. 5, 2020 /PRNewswire/ -- OC, California - If you've followed the Orange County real estate market for a while, you've undoubtedly heard of Ken Leaders as he's one of the most respected agents in town ...

 2020-12-05 19:09 

The Street

Correctional Service Canada Recognizes Volunteers And Winner Of Taylor Award...

OTTAWA, ON, Dec. 5, 2020 /CNW/ - The Correctional Service of Canada (CSC) has over 4500 volunteers who dedicate their time and energy to work with and support the offenders in our care and custody. As we mark International Volunteer Day, CSC would like to...

 2020-12-05 18:45 

The Street

Poseida Therapeutics Provides Update On Phase 1 Trial Of P-BCMA-101 At The 2020 American Society Of Hematology Annual Meeting...

SAN DIEGO, Dec. 5, 2020 /PRNewswire/ -- Poseida Therapeutics, Inc. PSTX, a clinical-stage biopharmaceutical company utilizing proprietary gene engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today reported...

 2020-12-05 18:30 

The Street

IGM Biosciences Presents First Clinical Data From IGM-2323 In Non-Hodgkin's Lymphoma At 2020 ASH Annual Meeting...

- 9 of 14 P atients S howed R eduction in T umor S ize, I ncluding T wo R ecently R eported C omplete R esponses - - Company to Host Conference Call and Webcast Today at 2:00 p.m. ET - MOUNTAIN VIEW, Calif., Dec. 05, 2020 (GLOBE NEWSWIRE) -- IGM Bioscienc...

 2020-12-05 18:00 

The Street

GeneTx And Ultragenyx Announce Presentation Of Phase 1/2 Data On Investigational GTX-102 In Patients With Angelman Syndrome...

Results presented at Foundation for Angelman Syndrome Therapeutics (FAST) Global Summit Additional data , including EEG findings, support prior initial indications of activity and there were no new adverse events SARASOTA, Fla. and NOVATO, Calif., Dec. 05...

 2020-12-05 17:46 

The Street

Genome Editing And Cellular Therapies Show Promise For Treating Blood Disorders, Cancers...

WASHINGTON, Dec. 5, 2020 /PRNewswire/ -- Three studies being presented during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition report promising results in the use of cutting-edge genome editing and cellular therapies for hard-to...

 2020-12-05 17:45 

The Street

AbbVie Presents Extended Follow-Up Data For Fixed Duration Treatment VENCLEXTA/VENCLYXTO (venetoclax) In Chronic Lymphocytic Leukemia (CLL)...

NORTH CHICAGO, Ill., Dec. 5, 2020 /PRNewswire/ -- AbbVie ABBV today announced new, updated results from the Phase 3 MURANO and CLL14 clinical trials evaluating VENCLEXTA /VENCLYXTO (venetoclax) fixed duration treatment combinations at the virtual 62 nd Am...

 2020-12-05 17:45 

The Street

Genentech Announces New Data Reinforcing The Long-Term Benefit Of Venclexta-Based Combination For People With Relapsed Or Refractory Chronic Lymphocytic Leukemia...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that new data from the pivotal Phase III MURANO and CLL14 studies support the efficacy of fixed-duration, chemotherapy-free Venclexta (venetoclax)-based combinations in c...

 2020-12-05 17:34 

The Street

Disease-Free Survival Data From CAPTIVATE Study Demonstrate Benefit Of IMBRUVICA (ibrutinib)-Based Regimen As Fixed Duration, First-Line Treatment For Patients With Chronic Lymphocytic Leukemia...

RARITAN, N.J., Dec. 5, 2020 /PRNewswire/ -- New data from the Phase 2 CAPTIVATE study were presented today during an oral session at the 2020 American Society of Hematology (ASH) Annual Meeting ( Abstract #123). The study evaluated the efficacy and safety...

 2020-12-05 17:31 

The Street

Syros Presents New Data From Phase 2 Clinical Trial Of SY-1425 And Announces Plans To Initiate Registration-Enabling Trial In MDS And Randomized Phase 2 Trial In AML...

Syros Pharmaceuticals SYRS, a leader in the development of medicines that control the expression of genes, today announced new clinical data from its Phase 2 trial evaluating SY-1425, its first-in-class selective retinoic acid receptor alpha (RAR) agonist...

 2020-12-05 17:31 

The Street

Syros Acquires Clinical-Stage Drug Candidate For Acute Promyelocytic Leukemia, Expanding Its Pipeline Of Targeted Therapies For Hematologic Malignancies...

Syros Pharmaceuticals SYRS, a leader in the development of medicines that control the expression of genes, today announced that it has acquired from Orsenix, LLC (Orsenix) all of its assets related to SY-2101, formerly known as ORH-2014, a novel oral form...

 2020-12-05 17:30 

The Street

Yescarta Is First CAR T-cell Therapy To Demonstrate High Response Rates And Durable Clinical Benefit In A Pivotal Indolent Non-Hodgkin Lymphoma Study...

Kite, a Gilead Company (Nasdaq: GILD), today announced results from the primary analysis of ZUMA-5, a global, multicenter, single-arm, open-label Phase 2 study evaluating Yescarta (axicabtagene ciloleucel) in adult patients with relapsed or refractory ind...

 2020-12-05 17:30 

The Street

Kura Oncology Presents First Clinical Data For Menin Inhibitor KO-539 At American Society Of Hematology Annual Meeting...

- Evidence of biologic activity observed in each dose-escalation cohort treated to date - - Clinical activity includes one CR in a patient with a NPM1 mutation and one CR in a patient with a SETD2/RUNX1 mutation - - Continuous daily dosing well tolerated ...

 2020-12-05 17:30 

The Street

Bristol Myers Squibb And Bluebird Bio Present Data Highlighting Anti-BCMA CAR T Cell Therapy, Ide-cel, In Relapsed And Refractory Multiple Myeloma At ASH 2020...

Bristol Myers Squibb BMY and bluebird bio, Inc. (Nasdaq: BLUE) today announced updated data evaluating the companies' investigational B-cell maturation antigen (BCMA) directed chimeric antigen receptor (CAR) T cell therapy, idecabtagene vicleucel (ide...

 2020-12-05 17:00 

The Street

Statement From The Chief Public Health Officer Of Canada On December 5, 2020...

OTTAWA, ON, Dec. 5, 2020 /CNW/ - In lieu of an in-person update to the media, Dr. Theresa Tam, Canada's Chief Public Health Officer, issued the following statement today: "As the resurgence of COVID-19 activity continues in Canada, we are tracking...

 2020-12-05 16:30 

The Street

10 Best Stocks in the Dow This Past Week: Walgreens Surges...

The top 10 best-performing stocks in the Dow Jones Industrial Average over the past week included Walgreens, Intel, Apple and Caterpillar....

 2020-12-05 16:00 

The Street

Hematologists Play Vital Role In Advancing COVID-19 Research, Potential Treatments...

WASHINGTON, Dec. 5, 2020 /PRNewswire/ -- There are now millions of cases worldwide of COVID-19 infection, caused by the new virus SARS-CoV-2. As cases continue to soar, researchers around the globe are working urgently to identify risk factors and possibl...

 2020-12-05 16:00 

The Street

Preclinical Data Demonstrate Anti-Viral Activity Of AlloVir's ALVR109, An Allogeneic, Off-the-Shelf SARS-CoV-2 Specific T Cell Therapy...

AlloVir (Nasdaq: ALVR), a late clinical-stage cell therapy company, today announced that preclinical data presented in an oral presentation at the 62nd American Society of Hematology (ASH) Annual Meeting, demonstrates selective antiviral activity of ALVR1...

 2020-12-05 15:59 

The Street

Sale Of The Offshore Construction & Cable-lay Vessel Connector...

STOCKHOLM, Sweden, Dec. 5, 2020 /PRNewswire/ -- Ocean Yield ASA ("Ocean Yield" or "Company") has today entered into an agreement to sell the offshore construction and cable-lay vessel Connector to a third party. The vessel is expected to b...

 2020-12-05 15:45 

The Street

MESO FINAL DEADLINE MONDAY: ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Reminds Mesoblast Limited Investors Of Important December 7 Deadline In Securities Class Action - MESO...

Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Mesoblast Limited MESO between April 16, 2019 and October 1, 2020, inclusive (the "Class Period"), of the important December 7, 2020 lead plaintiff deadline...

 2020-12-05 15:30 

The Street

Gamida Cell Presents Updated, Expanded Results From Phase 1 Study Of Natural Killer Cell Therapy GDA-201 At ASH Annual Meeting And Exposition...

Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious hematologic diseases, today announced in an oral presentation the updated and expanded results from a Phase 1 clinical study of GDA-201, an ...

 2020-12-05 15:30 

The Street

Sierra Oncology Presents Long-term Overall Survival And Sustained Efficacy Outcomes Data For Momelotinib At ASH Annual Meeting...

--Momelotinib demonstrates robust overall survival in both JAKi-nave and patients previously treated with ruxolitinib-- VANCOUVER, BC, Dec. 5, 2020 /PRNewswire/ - Sierra Oncology, Inc. (SRRA), a late-stage biopharmaceutical company on a quest to deliver t...

 2020-12-05 15:30 

The Street

Bioniz Announces Positive Clinical Data Of BNZ-1, First Anti-Cytokine Therapy To Demonstrate Efficacy In Treating Refractory Cutaneous T-Cell Lymphoma...

IRVINE, Calif., Dec. 5, 2020 /PRNewswire/ -- Bioniz Therapeutics, Inc., ("Bioniz") today announced positive clinical data in an oral presentation at the 62nd ASH Annual Meeting And Exposition ( ASH 2020) from the company's Phase 1/2 clinical s...

 2020-12-05 15:00 

The Street

New Data For TecartusTM Demonstrate Durable Responses At One Year Follow-Up In Relapsed Or Refractory Mantle Cell Lymphoma...

Kite, a Gilead Company (Nasdaq: GILD), today announced follow-up results from the pivotal ZUMA-2 trial of Tecartus (brexucabtagene autoleucel, formerly KTE-X19) in adult patients with relapsed or refractory mantle cell lymphoma (MCL). At a median follow-u...

 2020-12-05 15:00 

The Street

New Four-Year Data Show Long-Term Survival In Patients With Large B-Cell Lymphoma Treated With Yescarta In ZUMA-1 Trial...

Kite, a Gilead Company (Nasdaq: GILD), today announced four-year follow-up data from the pivotal ZUMA-1 trial of Yescarta (axicabtagene ciloleucel) in adult patients with refractory large B-cell lymphoma (LBCL). Among Yescarta-treated patients (modified i...

 2020-12-05 15:00 

The Street

Cannabis Stocks Watchlist: Keep an Eye on Aurora Cannabis...

See how cannabis stocks such as Aurora Cannabis, Cronos Group and Tilray performed in the market this week....

 2020-12-05 15:00 

The Street

Intellia Therapeutics Presents New Preclinical Data Supporting Its CRISPR/Cas9-Engineered TCR-T Cell Treatment For Acute Myeloid Leukemia At The 62nd ASH Annual Meeting...

L ead immuno -oncology development candidate NTLA-5001 show s high anti-tumor activity as promising cancer treatment in proof-of-concept mouse models of acute leukemia s P roprietary process enhance s tumor control in pre clinical models and enable s effi...

 2020-12-05 15:00 

The Street

Editas Medicine Announces Preclinical Data And Large-Scale Manufacturing Process For EDIT-301, In Development For The Treatment Of Sickle Cell Disease And Beta-Thalassemia...

Data support novel approach to develop and manufacture a best-in-class, durable medicine for people living with hemoglobinopathies IND filing for EDIT-301 planned by end of 2020 CAMBRIDGE, Mass., Dec. 05, 2020 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Na...

 2020-12-05 15:00 

The Street

Sysmex Inostics Presents Data At The American Society Of Hematology Annual Meeting Demonstrating Exquisite Sensitivity Of SafeSEQ NGS Technology For Detection Of Measurable Residual Disease In Acute M...

BALTIMORE, Dec. 5, 2020 /PRNewswire/ -- Sysmex Inostics, Inc., a global leader and pioneer in blood-based, high-sensitivity molecular testing for oncology, is presenting the poster "Ultrasensitive Measurable Residual Disease (MRD) Detection in Acute M...

 2020-12-05 15:00 

The Street

Fulcrum Therapeutics Presents Updated Data On Sickle Cell Disease Program At The 62nd American Society Of Hematology (ASH) Annual Meeting And Exposition...

CAMBRIDGE, Mass., Dec. 05, 2020 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that preclinical d...

 2020-12-05 14:55 

The Street

Hyperlink InfoSystem Positioned As One Of The Top App Development Companies In Kuwait...

KUWAIT CITY, Dec. 5, 2020 /PRNewswire/ -- Kuwait's IT market is all set to grow positively in 2021, after facing severe challenges in 2020 due to the COVID-19 outbreak. Looking ahead, there is a full scope of the economic recovery. Kuwait's positi...

 2020-12-05 14:37 

The Street

New Data From HARMONY Demonstrate The Power Of Big Data Analytics To Inform Personalized Medicine In Blood Cancer...

THE HAGUE, Netherlands, Dec. 5, 2020 /PRNewswire/ -- The HARMONY Alliance announces new analyses demonstrating how Big Data can facilitate personalized medicine in patients with blood cancers, also known as Hematologic Malignancies. Using data from around...

 2020-12-05 14:00 

The Street

The Top Crops and Commodities in the U.S....

Before you sit down to your holiday meal, take a moment to appreciate it -- and all the crops, animals, farmers and retailers who make it happen....

 2020-12-05 14:00 

The Street

10 Stocks Under $10 This Past Week: Blackberry Is Soaring...

Top performing stocks under $10 this past week include small-cap and penny stocks like Blackberry, United Microelectronics, Cemex and Banco Santander....

 2020-12-05 13:30 

The Street

ALERT: Halper Sadeh LLP Encourages IPHI, EIGI, ARA, And AKER Shareholders To Contact The Firm...

NEW YORK, Dec. 5, 2020 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following mergers: Inphi Corporation IPHI concerning potential violations of the federal securities laws and/or breaches of fiduc...

 2020-12-05 13:29 

The Street

XCMG Delivers Advanced Wheel Bulldozer To Mongolia, Improving Efficiency For Mining Industry...

XUZHOU, China, Dec. 5, 2020 /PRNewswire/ -- Leading construction machinery manufacturer XCMG (000425.SZ) has delivered a DL560 wheel bulldozer - its largest wheel loader - to Mongolia. The delivery marks full access for the Mongolia mining industry to XCM...

 2020-12-05 13:15 

The Street

XCMG Delivers 10 Units Of XCA1600 Super All-terrain Cranes At Bauma China 2020; Signs Multiple Deals Totaling CNY2 Billion On Opening Day...

SHANGHAI, Dec. 5, 2020 /PRNewswire/ -- XCMG (000425.SZ) delivered 10 units of XCA1600 all-terrain cranes on the opening day of bauma China 2020 in Shanghai. It's the smallest 1,600-ton super crane in size with the most considerable hoisting capability...

 2020-12-05 12:41 

The Street

ROSEN, GLOBAL INVESTOR COUNSEL, Announces Filing Of Securities Class Action Lawsuit Against Citigroup Inc.; Encourages Investors With Losses In Excess Of $100K To Contact The Firm - C...

NEW YORK, Dec. 5, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Citigroup Inc. C between January 15, 2016 and October 12, 2020, inclusive...

 2020-12-05 12:38 

The Street

U.S. (Un)Welcomes Chinese Students In 2021...

DENVER, Dec. 5, 2020 /PRNewswire/ -- China and US conflict, editing sphere loses and decrease of the economy. This was not what we had been expecting in 2020. Being the leader in the admissions editing sphere and working on the market since 1997, EssayEdg...

  • Need an account?  
    or